Medical Research Collaborative, LLC @MedResCol · 5m Careful with $MTNB here. Although I like MAT9001 quite a bit compared with Vascepa, and think it is superior, there is still a chance the FDA will issue a CRL to Amarin as early as next week. That would send MTNB back under $1.